adenine and gs-7340

adenine has been researched along with gs-7340 in 295 studies

Research

Studies (295)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (1.36)29.6817
2010's154 (52.20)24.3611
2020's137 (46.44)2.80

Authors

AuthorsStudies
Cihlar, T; Cundy, KC; Eisenberg, E; He, GX; Lee, WA; Mulato, A; Swaminathan, S1
Bischofberger, N; Blackwood, EJ; Colón, R; Kearney, BP; Lawson, JR; Lee, WA; Marthas, ML; Sexton, JJ; Van Rompay, KK1
Birkus, G; Cihlar, T; Gibbs, C; Kutty, N; Lee, W; Liu, X; MacArthur, H; McDermott, M; Swaminathan, S; Wang, R1
Birkus, G; Cihlar, T; He, GX; Kutty, N; Lee, W; McDermott, M; Mulato, A1
Babusis, D; Lee, WA; Phan, TK; Ray, AS; Watkins, WJ1
Adams, DR; Butler, K; Cong, ME; Garcia-Lerma, JG; Hanson, D; Hendry, RM; Heneine, W; Kersh, EN; Luo, W; McNicholl, JM; Youngpairoj, AS; Zheng, Q1
Lepist, EI; Maclennan, K; Murray, B; Phan, TK; Ray, AS; Roy, A; Tong, L1
Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L1
Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A1
Babusis, D; Bam, RA; Birkus, G; Cihlar, T; Yant, SR1
Bam, RA; Cihlar, T; Yant, SR1
Brar, I; Callebaut, C; Elion, R; Fordyce, MW; Martin, H; McCallister, S; Ortiz, R; Post, F; Sax, PE; Wang, H; Zolopa, A1
Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S1
Callebaut, C; Cao, H; Cheng, A; Crofoot, G; Custodio, J; Das, M; Flamm, JA; Gathe, J; Liu, HC; Martin, H; McCallister, S; McDonald, C; Mills, A; Saag, M; Scribner, A; Shalit, P; Shamblaw, D; Thomas, A; Yan, M1
Babusis, D; Hao, J; Lepist, EI; Murakami, E; Park, Y; Ray, AS; Wang, T1
Baeten, JM; Wyatt, C1
Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L1
Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F1
Callebaut, C; Johnson, A; Margot, NA; Miller, MD1
Callebaut, C; Miller, MD; Stepan, G; Tian, Y1
Bam, RA; Birkus, G; Cihlar, T; Frey, CR; Stray, KM; Tsai, L; Willkom, M; Yant, SR1
Andrade-Villanueva, J; Arribas, JR; Brar, I; Brunetta, J; Cavassini, M; Cheng, AK; DeJesus, E; DiPerri, G; Elion, R; Girard, PM; Huhn, G; Koenig, E; Liu, YP; Madruga, JV; McCallister, S; Mills, A; Orkin, C; Plummer, A; Shamblaw, D; Stephens, JL; Van Lunzen, J; Wohl, DA1
Fordyce, MW; Hitchcock, MJ; Ray, AS1
Wyatt, CM1
Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L1
Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD1
Aguiar, C; Antela, A; Boffito, M; Compston, J; Di Perri, G; Hendry, BM; Mallon, P; Pourcher-Martinez, V1
Dewar, RL; Kopp, JB; Lane, HC; Maldarelli, F; Manion, MM; Mikula, JM; Norman-Wheeler, JF; Ober, AG; Pau, AK; Suarez, LM1
Warpakowski, A1
Desai, T; Johengen, D; Luecke, E; McGowan, I; Rothrock, G; Schlesinger, E; van der Straten, A1
Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M1
Gazzard, B1
De Clercq, E2
Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F1
Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S1
Deeks, ED; Greig, SL1
Jones, R; Levy, JB; Milburn, J1
Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M1
Bischoff, M1
Babusis, D; Deyounks, F; García-Lerma, JG; Heneine, W; Massud, I; Miller, MD; Mitchell, J; Ray, AS; Rooney, JF1
Gibson, AK; Nambiar, PH; Schafer, JJ; Shah, BM1
Lu, X; Wang, H; Xu, N; Yang, X1
Bannerman, T; Cheng, A; Das, M; Dinoso, J; Fang, L; Fordyce, MW; Funderburg, NT; Kulkarni, M; Liu, HC; Mantini, J; McCallister, S; McComsey, GA; Song, Q; Thornton, B; Zhang, Y1
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L1
Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A1
Havlíčková, K; Husa, P; Snopková, S1
Kitrinos, KM; Liu, Y; Miller, MD1
Rizza, S; Sampath, R; Temesgen, Z; Zeuli, J1
Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y1
Babusis, D; Callebaut, C; Kitrinos, K; Liu, Y; Miller, M; Ray, A1
Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K1
Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP1
Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Lazzarin, A; Liu, HC; Mills, A; Orkin, C; Podzamczer, D; Porter, D; Quirk, E; Ramgopal, M; Rijnders, B; Rockstroh, J; Ruane, P; SenGupta, D; Stoeckle, M; Thalme, A; Vandercam, B1
Abram, ME; Bellos, N; Cheng, A; Clarke, A; Daar, E; Gallant, J; Henry, K; Orkin, C; Raffi, F; Rhee, MS; Santana-Bagur, J; Scarsella, A; Slama, L; Stein, DK; Yan, M1
Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA1
Callebaut, C; Cox, S; Johnson, A; Margot, N; Miller, M; Ram, R1
Cottrell, ML; Emerson, CW; Garrett, KL; Gay, C; Kashuba, ADM; McCallister, S; Peery, A; Prince, HMA; Rooney, JF; Schauer, A; Sykes, C1
Gotham, D; Hill, A; Pozniak, AL1
Boffito, M; Flexner, CW; Maartens, G1
Karris, MY1
Acharya, SK; Agarwal, K; Chan, HL; Chen, CY; Chowdhury, A; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Gane, E; Hui, AJ; Janssen, HL; Kim, HJ; Kitrinos, KM; Lim, YS; Lin, L; Massetto, B; McHutchison, JG; Mehta, R; Seto, WK; Subramanian, GM; Tsang, TY1
Acharya, SK; Brunetto, M; Buti, M; Cathcart, AL; Chan, HL; Chuang, WL; Flaherty, JF; Gaggar, A; Gane, E; Hui, AJ; Izumi, N; Janssen, HL; Kim, K; Lim, YS; Marcellin, P; Massetto, B; McHutchison, JG; Mehta, R; Pan, CQ; Seto, WK; Stepanova, T; Subramanian, GM1
Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P1
Abdul Basit, S; Dawood, A; Gish, R; Ryan, J1
Chan, HLY; Scott, LJ1
Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H1
Darcis, G; Moutschen, M; Sauvage, AS1
Gallagher, A; Gracey, DM; Quan, D1
Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D1
Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K1
Chen, Q; Jin, X; Ouyang, B; Peng, Y; Sun, J; Wang, G; Zhang, J; Zhen, L; Zhou, F1
Atta, MG; Choi, MJ; Fine, D; McMahon, BA; Novick, TK; Rosenberg, AZ1
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G1
Hsu, YC; Nguyen, MH; Wei, MT1
Ferrara, SM; Santantonio, T; Sica, S; Tartaglia, A1
Guaraldi, G1
Reinke, T1
Furusyo, N; Nguyen, MH; Ogawa, E1
Bodwell, J; Kashuba, ADM; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR1
Asriel, B; Chan, L; Eaton, EF; Wyatt, CM1
Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S1
Barth, A; Lai, MT; Ma, B; McHale, CM1
Grossi, G; Lampertico, P; Loglio, A; Viganò, M1
DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S1
Buti, M; Esteban, R; Riveiro-Barciela, M1
Ensign, LM; Hoang, T; Hummert, P; Marzinke, MA; Parsons, TL1
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K1
Callebaut, C; Cox, S; Margot, N; Miller, M1
Bowden, BH; Smith, DE; Tom, M1
Begley, R; Custodio, JM; Das, M; Kearney, BP; Ling, J; Zhong, L1
Satsangi, S1
Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT1
Clotet, B; Negredo, E1
Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW1
Deeks, ED1
Harris, M1
Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P1
Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D1
Alsunaid, SR; Ashraf, H; Soubani, AO1
Bares, SH; Havens, JP; Lee, SS; O'Neill, JL; Podany, AT; Sayles, HR; Scarsi, KK; Swindells, S1
Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B1
Aralaguppe, SG; Neogi, U; Njenda, DT; Rao, R; Sarafianos, SG; Singh, K; Sönnerborg, A1
Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N1
Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N1
Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F1
Bogner, JR; Gomez, M; Härter, G; Roider, J; Seybold, U1
Byland, E; Canupp, K; Dunlap, J; Mospan, C; Mospan, G; Whitaker, WB; Xiong, L1
Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Mena-De-Cea, Á; Míguez-Rey, E; Poveda, E; Vázquez-Rodríguez, P1
Bártolo, I; Borrego, P; Caixas, U; Gomes, P; Gonçalves, F; Pinto, IV; Taveira, N1
Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S1
Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N1
Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E1
Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM1
Ahn, A; Bae, HS; Chang, M; Fong, TL; Lee, BT; Lim, C; Tien, A1
Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G1
Bahr, NC; Yarlagadda, SG2
Mesplède, T; Pham, HT1
Bodwell, J; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR1
Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M1
Arabzadeh, V; Davallo, M; Goudarzi, N; Sohrabi, MR1
Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Mogyorosi, K1
Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L1
Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H1
Blake, K; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C1
Arends, JE; Hoepelman, AIM; Mudrikova, T; Thielen, MAJ; Van Welzen, BJ1
Fang, B; Ge, Q; Kang, X; Li, Z; Ma, H; Zhao, L; Zhou, Z1
Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y1
Barber, TJ1
Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X1
Di Perri, G; Esser, S; Lelièvre, JD; Parczewski, M; Shafran, SD1
Fujii, T; Kawasoe, K; Nitta, K; Ohta, A1
Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K1
Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P1
Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E1
Kaplun, O; Psevdos, G1
Chen, J; Cheng, J; Li, L; Ma, Y; Yu, Y; Zhao, J; Zhou, L1
Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A1
Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S1
Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M1
Kearney, B; Kolaris, C; Ling, KHJ; Majeed, SR; Tarnowski, T; Xiao, D; Zondlo, S1
Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY1
Coelho, LE; Grinsztejn, B; Landovitz, RJ; Torres, TS; Veloso, VG1
Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C1
Castagna, A; Gianotti, N1
Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y1
Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Furrer, H; Fux, CA; Kovari, H; Rauch, A; Roth, B; Stöckle, M; Surial, B; Wandeler, G1
Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H1
Álvarez, H; Llibre, JM1
Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S1
Saag, MS1
Goldstein, RH; Walensky, RP1
Bailey, AC; Barbini, B; Burling, K; Campbell, L; Hamzah, L; Ibrahim, F; Jones, R; Musso, CG; Post, FA; Williams, D1
Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Nishida, S; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M1
Chen, X; Cheng, J; Feng, S; Han, K; Han, M; Liang, P; Liu, S; Lu, H; Wang, Y; Yuan, X; Zhao, J; Zhou, L1
Arenas-Pinto, A; Berger, F; Mauss, S; Milinkovic, A1
Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H1
Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N1
Drak, D; Gracey, DM; O'Connor, CC; Templeton, DJ; Turner, D1
Blennow, K; Das, M; Gisslen, M; Hermansson, L; Makadzange, T; McCallister, S; Nilsson, S; Price, RW; Yilmaz, A; Zetterberg, H1
Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L1
Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J1
Di Perri, G; Shafran, SD1
Cain, CM; Dobek, G; Grasperge, B; Hope, T; Karunakaran, D; Kiser, PF; Marzinke, M; Pearson, E; Peet, MM; Qiu, J; Simpson, SM; Su, JT; Sung, S; Tfaily, EB; Veazey, R; Watrous, D; Widanapathirana, L1
Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB1
Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY1
Jaeger, H; Jonsson-Oldenbuettel, C; Noe, S1
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B1
Daskalakis, DC; Feinberg, J; Krakower, DS; Marcus, JL2
Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y1
Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB1
Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y1
Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J1
Chen, YS; German, P; Kearney, BP; Ling, KHJ; Ma, L; Majeed, SR; Tarnowski, T; Xiao, D; Zhang, T; Zhao, Y1
Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD1
Mak, LY1
Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK1
Brooks, KM; Dooley, KE; Eke, AC; Gebreyohannes, RD; Mirochnick, M; Sheffield, JS1
Armstrong, WS; Del Rio, C1
Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Günthard, HF; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Wandeler, G1
Berruti, M; Briano, F; Di Biagio, A; Taramasso, L1
Hooi, B; Leungsuwan, S; Myint, KS1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K1
Barco, EA; Cotter, AG; Feeney, E; Lacey, A; Lambert, JS; Macken, A; Mallon, PW; Muldoon, E; Savinelli, S; Sheehan, G; Tinago, W1
Agrahari, V; Banga, AK; Clark, MR; Doncel, GF; Gao, X; Jiang, Y; Peet, MM; Singh, ON; Zhang, W1
Anderson, J; Baker, JV; Fletcher, CV; Jorstad, S; Mykris, T; Podany, AT; Schacker, TW; Thorkelson, A; Winchester, LC1
Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M1
André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A1
Hill, A; Venter, WDF1
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J1
Gwenden, KN; Marzinke, MA; Parsons, TL1
Brainard, D; McCallister, S1
Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L1
Cattaneo, D; Filice, C; Gervasoni, C; Riva, A1
Spiegel, HML1
Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC1
Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH1
Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L1
Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO1
Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Chave, JP; Doco-Lecompte, T; Fehr, J; Furrer, H; Günthard, HF; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Walti, LN; Wandeler, G1
Freedberg, KA; Horn, T; McCann, NC; Paltiel, AD; Walensky, RP1
Bush, S; Das, M; Shreay, S; Ting, J1
Balcombe, SM; Hill, LA; Martin, TCS; Tang, ME1
Djan, K; Dorsey, HG; Jnr, DA; Li, M; Musoff, C; Paintsil, E; Schoen, N; Zhou, L1
Boffito, M; Emerson, M; Gazzard, B; Khawaja, AA; Lovell, AO; Nelson, M; Taylor, KA1
Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A1
Wong, GL; Yip, TC1
Gotham, D; Hill, A; Hughes, SL; McCann, K; Pepperrell, T; Pilkington, V; Pozniak, AL1
Wood, BR1
Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M1
Cao, L; Huang, Y; Pan, CQ1
Elmofti, Y; Gish, RG1
Gandhi, M; Robles, G; Sauermilch, D; Starks, TJ1
Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K1
Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A1
Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG1
Chen, G; Chen, SH; Fu, YM; Ji, D; Li, L; Li, ZB; Liu, Y; Niu, XX; Shao, Q; Wang, CY1
Abdel-Razeq, SA; Nasr, ZA; Said, NS1
Mesplède, T1
Bonomini, M; Di Liberato, L; Piscitani, L; Pontolillo, M; Ucciferri, C; Vecchiet, J1
Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E1
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L1
Breslin, PAS; Choma, K; Christensen, CM; Flammer, LJ; Jiang, P; Margolskee, RF; Ozdener, MH; Rawson, NE; Rivers, N; Schwiebert, E; Streiff, J; Wang, Y; Xi, R1
Baum, MM; Demkovich, ZR; Diana, F; Dobard, C; Feldman, PL; Garcia-Lerma, JG; Grattoni, A; Gunawardana, M; Ho, DK; Hope, TJ; Massud, I; Milad, M; Moss, JA; Pons-Faudoa, FP; Roller, S; Romano, JW; Srinivasan, S; van der Straten, A; Veazey, RS; Zane, D1
Gandhi, M; Glidden, DV; Johnson, KA; Okochi, H; Spinelli, M1
Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC1
Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L1
Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M1
Buti, M; Esteban, R; Marcos-Fosch, C1
Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY1
Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D1
Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D1
Carneiro, PB; D'Angelo, AB; Grov, C; Johnson, J; Westmoreland, DA1
Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK1
Avihingsanon, A; Avihingsanon, Y; Gatechompol, S; Iampenkhae, K; Surintrspanont, J; Udomkarnjananun, S; Ueaphongsukkit, T1
Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K1
Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A1
Alnouti, Y; Bade, AN; Cobb, DA; Cohen, SM; Deodhar, S; Edagwa, B; Gautam, N; Gendelman, HE; McMillan, J; Shetty, BLD; Smith, N1
Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML1
Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF1
Lyu, J; Pan, L; Teng, J; Wu, H; Zhang, F; Zhang, M; Zhu, C1
Bazzi, R; Roa, PE1
Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY1
Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F1
Jeong, J; Jung, SW; Park, EJ; Park, NH; Shin, JW1
Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ1
Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S1
Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N2
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B1
Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y1
Lin, HY; Tseng, TC1
Kamiya, K; Kishimoto, M; Komine, M; Kuwahara, A; Morimoto, N; Ohtsuki, M; Sugai, J1
Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM1
Choi, J; Choi, WM; Kim, KM; Lee, D; Lee, HC; Lim, J; Lim, YS; Shim, JH1
Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL1
Cheng, AK; Lee, WA1
Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K1
Berenguer, J; Blair, C; Chuck, SK; D'Antoni, ML; De Wit, S; Gallant, J; Haubrich, R; Maggiolo, F; Martin, H; McNicholl, IR; Molina, JM; Piontkowsky, D; Pulido, F; Rizzardini, G; Vandekerckhove, L1
Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S1
Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A1
Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME1
Cerankowski, J; Keith, SW; Schafer, JJ; Shimada, A; Walshe, C; Zimmerman, M1
Agorastou, P; Dalekos, GN; Deutsch, M; Elefsiniotis, I; Gatselis, N; Goulis, J; Kapatais, A; Karaoulani, T; Karatapanis, S; Kranidioti, H; Kyriazidou, A; Manesis, E; Manolakopoulos, S; Mimidis, K; Mylopoulou, T; Papatheodoridi, M; Papatheodoridis, GV; Samonakis, D; Sevastianos, V; Triantos, C; Vasiliadis, T; Zisimopoulos, K1
Chen, YC; Chien, RN; Hsu, CW; Tai, DI1
Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY1
Parveen, S; Shah, A; Singh, J; Tiwari, A1
Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E1
Kumar, M1
Gane, E; Kashuba, A; Levy, MT1
Lee, MH1
Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M1
Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; de Gea Grela, A; de Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Moreno, V; Pérez Valero, I; Serrano, L; Valencia, E1
Papatheodoridis, GV1
Chen, CH; Tseng, TN1
Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI1
Chen, EQ; Wang, ML1
Ogawa, E1
Liu, W; Yan, B; Yu, S1
Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y1
Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M1
Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW1
Buscemi, L; Mossholder, B1
Ondrush, NM; Sidman, EF1
Alcalá, JC; Castro, A; Grau, S; Miró, JM; Olalla, J; Rubio-Rodríguez, D; Rubio-Terrés, C1
Eckardt, PA; Montalvo, S; Partosh, D; Sherman, EM; Unger, N1
Assoumou, L; Bachelard, A; Benalycherif, A; Charpentier, C; Descamps, D; Donadille, C; Duvivier, C; El Mouhebb, M; Ghosn, J; Isernia, V; Lacombe, K; Landman, R; Mora, M; Peytavin, G; Spire, B1
Allard, SD; Ausselet, N; Darcis, G; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Messiaen, P; Nasreddine, R; Van Praet, J; Vandekerckhove, L; Yombi, JC1
Guevara-Maldonado, MF; Kammar-García, A; Mancilla-Galindo, J; Mata-Marín, JA; Ortiz-Hernández, A; Pérez-Barragán, E; Pérez-Cavazos, S1
Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J1
Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ1

Reviews

38 review(s) available for adenine and gs-7340

ArticleYear
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Antiviral research, 2016, Volume: 125

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Stability; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Kidney; Prodrugs; Tenofovir; Virus Replication

2016
The role of tenofovir alafenamide in future HIV management.
    HIV medicine, 2016, Volume: 17 Suppl 2

    Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Prodrugs; Tenofovir; Treatment Outcome

2016
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    Biochemical pharmacology, 2016, Nov-01, Volume: 119

    Topics: Adenine; Alanine; Antiviral Agents; HIV Infections; Humans; Tenofovir

2016
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Drugs, 2016, Volume: 76, Issue:9

    Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir

2016
Renal effects of novel antiretroviral drugs.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir

2017
Tenofovir Alafenamide.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:11

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Density; Female; HIV Infections; HIV-1; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tablets; Tenofovir

2016
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
    Medicine, 2016, Volume: 95, Issue:41

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Treatment Outcome

2016
Tenofovir alafenamide (Vemlidy) for hepatitis B.
    The Medical letter on drugs and therapeutics, 2017, Jan-02, Volume: 59, Issue:1511

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Tenofovir

2017
Tenofovir alafenamide fumarate for the treatment of HIV infection.
    Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:11

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Tenofovir

2016
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.
    Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir

2017
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:4

    Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir

2017
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:7

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Time Factors

2017
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
    Drugs, 2017, Volume: 77, Issue:9

    Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Randomized Controlled Trials as Topic; Tenofovir

2017
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:11

    Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Male; Osteoporosis; Patient Safety; Pregnancy; Renal Insufficiency; Risk Factors; Tenofovir; Treatment Outcome

2017
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecular Conformation; Tenofovir

2017
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
    Biochemical pharmacology, 2018, Volume: 153

    Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome

2018
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
    Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Kidney Diseases; Pre-Exposure Prophylaxis; Prodrugs; Tenofovir

2018
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Expert review of anti-infective therapy, 2018, Volume: 16, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Humans; Prodrugs; Renal Insufficiency; Tenofovir

2018
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38 Suppl 1

    Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome

2018
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Drugs, 2018, Volume: 78, Issue:10

    Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome

2018
Tolerability of Current Antiretroviral Single-Tablet Regimens
    AIDS reviews, 2018, Volume: 20, Issue:3

    Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir

2018
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
    Drug design, development and therapy, 2018, Volume: 12

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir

2018
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:3

    Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration

2019
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:4

    Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans; Incidence; Male; Middle Aged; Renal Insufficiency; Tenofovir; Young Adult

2019
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
    HIV medicine, 2019, Volume: 20 Suppl 7

    Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Disease Management; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Life Style; Tenofovir; Treatment Outcome

2019
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
    The lancet. HIV, 2019, Volume: 6, Issue:11

    Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxyadenosines; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir

2019
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:11

    Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir

2019
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 93

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kidney; Randomized Controlled Trials as Topic; Tablets; Tenofovir

2020
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Expert opinion on drug metabolism & toxicology, 2020, Volume: 16, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Lactation; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tenofovir

2020
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
    AIDS (London, England), 2020, 12-01, Volume: 34, Issue:15

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir

2020
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:10

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Tenofovir

2021
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
    AIDS research and human retroviruses, 2021, Volume: 37, Issue:6

    Topics: Adenine; Adolescent; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2021
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
    AIDS research and therapy, 2021, 08-21, Volume: 18, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Tenofovir

2021
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
    Alimentary pharmacology & therapeutics, 2022, Volume: 55, Issue:8

    Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir

2022
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 08-05, Volume: 79, Issue:16

    Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load

2022
Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 02-15, Volume: 80, Issue:4

    Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Pyridones

2023
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
    Expert review of anti-infective therapy, 2023, Volume: 21, Issue:1

    Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans

2023

Trials

59 trial(s) available for adenine and gs-7340

ArticleYear
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Journal of acquired immune deficiency syndromes (1999), 2013, Aug-01, Volume: 63, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nausea; Organophosphates; Organophosphonates; RNA, Viral; Single-Blind Method; Statistics, Nonparametric; Tenofovir; Viral Load; Young Adult

2013
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Plasma; Prodrugs; Tenofovir; Young Adult

2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
    Journal of acquired immune deficiency syndromes (1999), 2014, Sep-01, Volume: 67, Issue:1

    Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte Count; Cholesterol; Creatinine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Prodrugs; Proteinuria; RNA, Viral; Tenofovir; United States

2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
    Journal of hepatology, 2015, Volume: 62, Issue:3

    Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Young Adult

2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Journal of acquired immune deficiency syndromes (1999), 2015, Aug-01, Volume: 69, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Tenofovir

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load

2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Viral Load

2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
    Journal of acquired immune deficiency syndromes (1999), 2016, May-01, Volume: 72, Issue:1

    Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir

2016
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
    HIV clinical trials, 2016, Volume: 17, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult

2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
    The lancet. HIV, 2016, Volume: 3, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir

2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
    Journal of acquired immune deficiency syndromes (1999), 2016, 11-01, Volume: 73, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome

2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
    EBioMedicine, 2016, Volume: 13

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbidity; Female; HIV Infections; HIV-1; Humans; Inflammation Mediators; Male; ROC Curve; Tenofovir

2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    The lancet. HIV, 2016, Volume: 3, Issue:12

    Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load

2016
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    The lancet. HIV, 2017, Volume: 4, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult

2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
    The lancet. HIV, 2017, Volume: 4, Issue:5

    Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir

2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    The lancet. HIV, 2017, Volume: 4, Issue:5

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Tenofovir

2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
    Journal of acquired immune deficiency syndromes (1999), 2017, 06-01, Volume: 75, Issue:2

    Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Middle Aged; Tenofovir; Treatment Outcome; Viral Load

2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
    Journal of acquired immune deficiency syndromes (1999), 2017, 06-01, Volume: 75, Issue:2

    Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States

2017
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.
    The Journal of antimicrobial chemotherapy, 2017, 06-01, Volume: 72, Issue:6

    Topics: Adenine; Adult; Alanine; Cervix Uteri; Drug Administration Schedule; Epithelial Cells; Female; Gastrointestinal Tract; Humans; Intestinal Mucosa; Leukocytes, Mononuclear; Middle Aged; Mucous Membrane; Organophosphates; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Tissue Distribution; Vagina; Young Adult

2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult

2016
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
    Clinical pharmacology in drug development, 2018, Volume: 7, Issue:2

    Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir

2018
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult

2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
    Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult

2017
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome

2018
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
    Journal of acquired immune deficiency syndromes (1999), 2018, 06-01, Volume: 78, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis B e Antigens; Humans; Male; Middle Aged; Tenofovir; Young Adult

2018
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
    The lancet. HIV, 2018, Volume: 5, Issue:7

    Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult

2018
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
    The patient, 2018, Volume: 11, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult

2018
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:4

    Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult

2019
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 09-27, Volume: 69, Issue:8

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir

2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome

2019
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Journal of medical virology, 2019, Volume: 91, Issue:10

    Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir

2019
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
    Antiviral research, 2019, Volume: 170

    Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load

2019
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    The Journal of antimicrobial chemotherapy, 2019, 12-01, Volume: 74, Issue:12

    Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir

2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    AIDS research and therapy, 2019, 08-29, Volume: 16, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult

2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
    The lancet. HIV, 2019, Volume: 6, Issue:10

    Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir

2019
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Journal of acquired immune deficiency syndromes (1999), 2019, 11-01, Volume: 82, Issue:3

    Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult

2019
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    HIV medicine, 2020, Volume: 21, Issue:3

    Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Linear Models; Male; Middle Aged; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; United Kingdom

2020
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 02-14, Volume: 70, Issue:5

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir

2020
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    PloS one, 2019, Volume: 14, Issue:12

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Middle Aged; Neurofilament Proteins; Tenofovir

2019
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    AIDS (London, England), 2020, 04-01, Volume: 34, Issue:5

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load

2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 11-05, Volume: 71, Issue:8

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug Substitution; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nasopharyngitis; Renal Insufficiency; Respiratory Tract Infections; Sustained Virologic Response; Tenofovir

2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Journal of acquired immune deficiency syndromes (1999), 2020, 07-01, Volume: 84, Issue:3

    Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Cross-Over Studies; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Polyphosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult

2020
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
    BMC infectious diseases, 2020, Jul-20, Volume: 20, Issue:1

    Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome

2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
    The lancet. HIV, 2020, Volume: 7, Issue:10

    Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult

2020
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Antimicrobial agents and chemotherapy, 2021, 05-18, Volume: 65, Issue:6

    Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Healthy Volunteers; HIV Infections; HIV-1; Humans; Male; Tenofovir

2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
    Lancet (London, England), 2021, 04-03, Volume: 397, Issue:10281

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal

2021
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    BMC infectious diseases, 2021, Jun-14, Volume: 21, Issue:1

    Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome

2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    The lancet. HIV, 2021, Volume: 8, Issue:7

    Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult

2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
    Journal of acquired immune deficiency syndromes (1999), 2021, 09-01, Volume: 88, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load

2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
    Journal of acquired immune deficiency syndromes (1999), 2021, 12-01, Volume: 88, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult

2021
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir

2022
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
    HIV medicine, 2023, Volume: 24, Issue:1

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir

2023
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
    Medicine, 2022, Sep-30, Volume: 101, Issue:39

    Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome

2022
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
    The Journal of antimicrobial chemotherapy, 2023, 11-06, Volume: 78, Issue:11

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry

2023

Other Studies

198 other study(ies) available for adenine and gs-7340

ArticleYear
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:5

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Area Under Curve; CD4-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Dogs; HIV-1; Humans; In Vitro Techniques; Lymphatic System; Male; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Spectrophotometry, Ultraviolet; Tenofovir; Tissue Distribution

2005
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 43, Issue:1

    Topics: Adenine; Administration, Oral; Administration, Topical; Alanine; Animals; Anti-HIV Agents; Genetic Predisposition to Disease; Macaca mulatta; Organophosphonates; Prodrugs; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Virulence

2006
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Adenine; Alanine; Anti-Retroviral Agents; Catalysis; Cathepsin A; Cell Size; Cells, Cultured; Enzyme Activation; Fibroblasts; Humans; Hydrolysis; Kinetics; Monocytes; Prodrugs; Recombinant Proteins; Substrate Specificity; Tenofovir

2007
Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases.
    Molecular pharmacology, 2008, Volume: 74, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; beta-N-Acetylhexosaminidases; Biomarkers; Cathepsin A; Cells, Cultured; Enzyme Activation; Humans; Hydrolysis; Kinetics; Leukocytes, Mononuclear; Lysosomes; Molecular Structure; Organophosphonates; Peptide Hydrolases; Prodrugs; Reverse Transcriptase Inhibitors; Serine Endopeptidases; Subcellular Fractions; Substrate Specificity; Tenofovir

2008
Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.
    Molecular pharmaceutics, 2013, Feb-04, Volume: 10, Issue:2

    Topics: Adenine; Administration, Oral; Alanine; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cathepsin A; Chromatography, Liquid; Dogs; Humans; Intestinal Absorption; Lymphocytes; Male; Prodrugs; Tandem Mass Spectrometry; Tenofovir

2013
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.
    The Journal of infectious diseases, 2012, Sep-01, Volume: 206, Issue:5

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytokines; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Longitudinal Studies; Macaca mulatta; Male; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Statistics, Nonparametric; Tenofovir; Viremia

2012
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:10

    Topics: Adenine; Alanine; Caco-2 Cells; Carbamates; Cobicistat; HIV Protease Inhibitors; Humans; Intestinal Absorption; Tenofovir; Thiazoles

2012
Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.
    Antiviral therapy, 2014, Volume: 19, Issue:7

    Topics: Adenine; Alanine; Anti-HIV Agents; Antiviral Agents; Cathepsin A; CD4-Positive T-Lymphocytes; Cells, Cultured; Enzyme Activation; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Tenofovir; Tissue Donors

2014
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
    Antiviral therapy, 2014, Volume: 19, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Biological Transport; Cell Line; Cells, Cultured; Gene Expression; Humans; Kidney Tubules, Proximal; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Tenofovir

2014
Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:6

    Topics: Adenine; Alanine; Animals; Cells, Cultured; Dogs; Hepatitis B virus; Hepatocytes; Humans; Liver; Male; Organophosphates; Tenofovir

2015
Tenofovir alafenamide for HIV infection: is less more?
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles

2015
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Drug Implants; Equipment Design; HIV Infections; HIV-1; Male; Monocytes; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir

2015
Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10

    Topics: Adenine; Alanine; Amino Acid Substitution; Anti-HIV Agents; Biotransformation; Cell Line; Clone Cells; Drug Resistance, Viral; Drug Stability; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Microbial Sensitivity Tests; Mutation; Primary Cell Culture; Prodrugs; Tenofovir; Virus Replication

2015
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10

    Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Cell Line; Culture Media; Drug Stability; Genotype; Herpesvirus 2, Human; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Microbial Sensitivity Tests; Primary Cell Culture; Prodrugs; Serum; Tenofovir; Virus Replication

2015
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Carboxylic Ester Hydrolases; Cathepsin A; CD4-Positive T-Lymphocytes; Cobicistat; Drug Interactions; Gene Expression; HEK293 Cells; HeLa Cells; HIV-1; Host-Pathogen Interactions; Humans; Oligopeptides; Primary Cell Culture; Prodrugs; Proline; RNA, Small Interfering; Serine Proteinase Inhibitors; Tenofovir

2016
Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
    Kidney international, 2016, Volume: 89, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials, Phase III as Topic; Creatinine; Drug Approval; Drug Combinations; Glomerular Filtration Rate; Humans; Kidney Tubules, Proximal; Prodrugs; Tenofovir

2016
Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
    Antiviral therapy, 2016, Volume: 21, Issue:6

    Topics: Acute Kidney Injury; Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Salvage Therapy; Tenofovir

2016
[New NRTI with optimized long-term tolerance].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Drug Tolerance; HIV Infections; Humans; Tenofovir

2015
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
    Pharmaceutical research, 2016, Volume: 33, Issue:7

    Topics: Adenine; Alanine; Anti-HIV Agents; Biodegradable Plastics; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Fumarates; HIV-1; Particle Size; Polyesters; Polymers; Pre-Exposure Prophylaxis; Solubility; Tenofovir

2016
Editorial.
    HIV medicine, 2016, Volume: 17 Suppl 2

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir

2016
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS (London, England), 2016, 06-01, Volume: 30, Issue:9

    Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome

2016
[Brief notes. Approval recommendation for fixed combination Descovy(R) in treatment of HIV].
    MMW Fortschritte der Medizin, 2016, Apr-14, Volume: 158, Issue:7

    Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tenofovir; Young Adult

2016
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9

    Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Case-Control Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Tenofovir

2016
[Optimized therapy].
    MMW Fortschritte der Medizin, 2016, Jun-09, Volume: 158 Suppl 1

    Topics: Adenine; Alanine; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Europe; HIV Infections; Humans; Tenofovir

2016
Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
    The Journal of infectious diseases, 2016, 10-01, Volume: 214, Issue:7

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Emtricitabine; Macaca; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome

2016
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
    Infectious diseases (London, England), 2017, Volume: 49, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir

2017
[Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Klinicka mikrobiologie a infekcni lekarstvi, 2016, Volume: 22, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Tenofovir

2016
Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
    Antiviral research, 2017, Volume: 139

    Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Genotype; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Mutagenesis, Site-Directed; Phenotype; Prodrugs; Tenofovir; Virus Replication

2017
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
    AIDS (London, England), 2017, 02-20, Volume: 31, Issue:4

    Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load

2017
Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adenine; Alanine; Cell Survival; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Female; Humans; Male; Osteoblasts; Tenofovir; Time Factors

2017
Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
    Antiviral research, 2017, Volume: 143

    Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Evolution, Molecular; Genotype; HEK293 Cells; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Phenotype; Prodrugs; Recombination, Genetic; Tenofovir

2017
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:7

    Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome

2017
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    The Journal of infectious diseases, 2017, 03-15, Volume: 215, Issue:6

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States

2017
[Update in HIV therapy: tenofovir alafenamide].
    Revue medicale suisse, 2016, Aug-24, Volume: 12, Issue:527

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Tenofovir

2016
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Internal medicine journal, 2017, Volume: 47, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseases; Middle Aged; Proteinuria; Tenofovir

2017
Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
    Journal of pharmaceutical and biomedical analysis, 2017, Nov-30, Volume: 146

    Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line, Tumor; Chromatography, Liquid; DNA Replication; Half-Life; Hep G2 Cells; Hepatocytes; HIV Infections; HIV-1; Humans; Organophosphates; Prodrugs; Tandem Mass Spectrometry; Tenofovir; Virus Replication

2017
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
    Medicine, 2017, Volume: 96, Issue:36

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitochondria; Prodrugs; Tenofovir

2017
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
    Journal of acquired immune deficiency syndromes (1999), 2018, 01-01, Volume: 77, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome

2018
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS (London, England), 2017, 10-23, Volume: 31, Issue:16

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Renal Dialysis; Tenofovir; Treatment Outcome

2017
Role of tenofovir alafenamide in the jungle of antiretroviral prescription.
    The Journal of antimicrobial chemotherapy, 2018, 01-01, Volume: 73, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Tenofovir

2018
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.
    Managed care (Langhorne, Pa.), 2017, Volume: 26, Issue:9

    Topics: Adenine; Alanine; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome

2017
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
    Scientific reports, 2017, 12-18, Volume: 7, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Contraceptive Agents; Contraceptives, Oral, Hormonal; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphates; Progestins; Tenofovir

2017
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    AIDS (London, England), 2018, 03-27, Volume: 32, Issue:6

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Substitution; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Plasma; Prospective Studies; Tandem Mass Spectrometry; Tenofovir; Young Adult

2018
Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
    Antiviral research, 2018, Volume: 151

    Topics: Adenine; Alanine; Anti-HIV Agents; Cytoplasm; Databases, Factual; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Meta-Analysis as Topic; Organophosphates; Prodrugs; Tenofovir; Viral Load; Virus Replication

2018
Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Journal of pharmaceutical and biomedical analysis, 2018, Apr-15, Volume: 152

    Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Humans; Organophosphonates; Prodrugs; Tandem Mass Spectrometry; Tenofovir

2018
Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:5

    Topics: Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, Missense; Selection, Genetic; Tenofovir

2018
Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
    International journal of STD & AIDS, 2018, Volume: 29, Issue:10

    Topics: Adenine; Alanine; Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Australia; HIV Infections; HIV-1; Humans; Medical Audit; Tenofovir; Treatment Outcome

2018
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
    Journal of acquired immune deficiency syndromes (1999), 2018, 08-01, Volume: 78, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine; Anti-Retroviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Tenofovir; Young Adult

2018
To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:6

    Topics: Adenine; Alanine; Anti-HIV Agents; Guanine; HIV Infections; Humans; Tenofovir

2018
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:8

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir

2018
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 138

    Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HIV Infections; HIV-1; Homosexuality, Male; Male; Mice; Organophosphates; Organophosphonates; Pre-Exposure Prophylaxis; Prodrugs; Rectum; Sexual and Gender Minorities; Tenofovir

2019
What did we learn from the bictegravir switch studies?
    The lancet. HIV, 2018, Volume: 5, Issue:7

    Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir

2018
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:5

    Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis C; HIV Infections; Humans; Male; Multiple Myeloma; Tenofovir; Transplantation, Autologous

2018
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
    BMC infectious diseases, 2018, 07-06, Volume: 18, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cross-Sectional Studies; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Health Knowledge, Attitudes, Practice; Health Surveys; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Pharmacists; Tenofovir

2018
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
    JCI insight, 2018, 07-12, Volume: 3, Issue:13

    Topics: Actinobacteria; Adenine; Alanine; Anti-Retroviral Agents; Bacteria; Endocytosis; Female; Gardnerella vaginalis; HIV Infections; Humans; Hydrogen-Ion Concentration; Jurkat Cells; Lactobacillus crispatus; Microbiota; Pyrimidines; Tenofovir; Vagina

2018
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
    The Journal of antimicrobial chemotherapy, 2018, 10-01, Volume: 73, Issue:10

    Topics: Adenine; Alanine; Anti-Retroviral Agents; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure

2018
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
    Infection, 2019, Volume: 47, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir

2019
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult

2018
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Infection, 2019, Volume: 47, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cohort Studies; Female; Fumarates; Germany; HIV Seropositivity; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain; Weight Loss

2019
Drug updates and approvals: 2018 in review.
    The Nurse practitioner, 2018, Volume: 43, Issue:12

    Topics: Adenine; Alanine; Amides; Aminophenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Clonidine; Doxylamine; Drug Approval; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Piperazines; Pyridones; Pyridoxine; Quinolones; Tenofovir; United States; United States Food and Drug Administration

2018
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Basic & clinical pharmacology & toxicology, 2019, Volume: 124, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Risk Factors; Spain; Tenofovir; Young Adult

2019
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2.
    Antiviral research, 2019, Volume: 161

    Topics: Adenine; Alanine; Anti-HIV Agents; Drug Discovery; Drug Resistance, Multiple, Viral; HIV-2; Humans; Microbial Sensitivity Tests; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication

2019
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
    AIDS (London, England), 2019, 02-01, Volume: 33, Issue:2

    Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pelvic Bones; Phosphorous Acids; Prospective Studies; Spine; Tenofovir; Treatment Outcome; Young Adult

2019
Fanconi Syndrome and Tenofovir Alafenamide: A Case Report.
    Annals of internal medicine, 2019, 06-04, Volume: 170, Issue:11

    Topics: Adenine; Alanine; Antiviral Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Tenofovir

2019
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
    Scientific reports, 2019, 02-12, Volume: 9, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cervix Uteri; Drug Resistance, Multiple; Endometrium; Epithelial Cells; Female; Fibroblasts; Genitalia, Female; HIV Infections; Humans; Middle Aged; Organophosphates; Tenofovir; Vagina

2019
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir

2019
Using artificial neural network and multivariate calibration methods for simultaneous spectrophotometric analysis of Emtricitabine and Tenofovir alafenamide fumarate in pharmaceutical formulation of HIV drug.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2019, May-15, Volume: 215

    Topics: Adenine; Alanine; Anti-HIV Agents; Calibration; Emtricitabine; Least-Squares Analysis; Multivariate Analysis; Neural Networks, Computer; Spectrophotometry, Ultraviolet; Tenofovir

2019
Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2.
    Diagnostic microbiology and infectious disease, 2019, Volume: 94, Issue:2

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiviral Agents; Dogs; Madin Darby Canine Kidney Cells; Membrane Transport Proteins; Reverse Transcriptase Inhibitors; Tenofovir

2019
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2019, Volume: 116, Issue:4

    Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome

2019
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
    Clinical pharmacology and therapeutics, 2019, Volume: 106, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cell Count; Emtricitabine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Plasma; Semen; Tenofovir; Tissue Distribution

2019
Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Resorption; Drug Substitution; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Retrospective Studies; Tenofovir

2019
Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019, Jun-01, Volume: 1117

    Topics: Adenine; Adolescent; Adult; Alanine; Chromatography, Liquid; Female; Humans; Limit of Detection; Linear Models; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry; Tenofovir; Young Adult

2019
Bictegravir and dolutegravir: head to head at 96 weeks.
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir

2019
A case of entecavir-induced Fanconi syndrome.
    CEN case reports, 2019, Volume: 8, Issue:4

    Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B, Chronic; Humans; Hypokalemia; Hypophosphatemia; Male; Nucleosides; Tenofovir; Treatment Outcome; Withholding Treatment

2019
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:3

    Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir

2020
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, 08-01, Volume: 76, Issue:16

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir

2019
Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway.
    Respiratory research, 2019, Jul-22, Volume: 20, Issue:1

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Bleomycin; Cells, Cultured; DNA-Binding Proteins; Fibroblasts; Humans; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Signal Transduction; Smad3 Protein; Tenofovir; Transforming Growth Factor beta1; Up-Regulation

2019
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Journal of acquired immune deficiency syndromes (1999), 2019, 11-01, Volume: 82, Issue:3

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult

2019
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    The Journal of infectious diseases, 2019, 10-22, Volume: 220, Issue:11

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina

2019
The determination of human peripheral blood mononuclear cell counts using a genomic DNA standard and application in tenofovir diphosphate quantitation.
    Analytical biochemistry, 2019, 11-15, Volume: 585

    Topics: Adenine; Alanine; Cell Count; Chromatography, High Pressure Liquid; DNA; Fluorescent Dyes; Genomics; Humans; Image Cytometry; Intercalating Agents; Leukocytes, Mononuclear; Organophosphates; Prodrugs; Tandem Mass Spectrometry; Tenofovir

2019
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-14, Volume: 71, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir

2020
Switching antiretrovirals in older patients.
    The lancet. HIV, 2019, Volume: 6, Issue:10

    Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir

2019
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
    BMC infectious diseases, 2019, Oct-10, Volume: 19, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Risk Factors; Switzerland; Tenofovir

2019
Fanconi Syndrome and Tenofovir Alafenamide.
    Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8

    Topics: Adenine; Alanine; Anti-HIV Agents; Fanconi Syndrome; Humans; Tenofovir

2019
Fanconi Syndrome and Tenofovir Alafenamide.
    Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8

    Topics: Adenine; Alanine; Anti-HIV Agents; Fanconi Syndrome; Humans; Tenofovir

2019
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 10-15, Volume: 69, Issue:9

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States

2019
HIV 101: fundamentals of antiretroviral therapy.
    Topics in antiviral medicine, 2019, Volume: 27, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load

2019
Where Were the Women? Gender Parity in Clinical Trials.
    The New England journal of medicine, 2019, Dec-26, Volume: 381, Issue:26

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; United States; United States Food and Drug Administration

2019
Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
    International journal of STD & AIDS, 2019, Volume: 30, Issue:13

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; beta 2-Microglobulin; Biomarkers; CD4 Lymphocyte Count; Creatinine; Fatty Acid-Binding Proteins; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load

2019
TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways.
    Hepatology international, 2020, Volume: 14, Issue:1

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Carbon Tetrachloride; Disease Models, Animal; DNA-Binding Proteins; Liver Cirrhosis, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Smad3 Protein; Tenofovir; Transforming Growth Factor beta

2020
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
    AIDS (London, England), 2019, 12-01, Volume: 33, Issue:15

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Drug Substitution; Female; Germany; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load

2019
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Journal of medical virology, 2020, Volume: 92, Issue:3

    Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome

2020
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    AIDS research and therapy, 2019, 12-07, Volume: 16, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Hospitals, Urban; Humans; Kidney Function Tests; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Tenofovir

2019
Response to Noe, Oldenbuettel and Jaeger.
    HIV medicine, 2020, Volume: 21, Issue:6

    Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir

2020
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Antimicrobial agents and chemotherapy, 2020, 02-21, Volume: 64, Issue:3

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Drug Implants; Female; Fumarates; HIV Infections; Humans; Inflammation; Macaca mulatta; Male; Necrosis; Polyurethanes; Rabbits; Subcutaneous Tissue; Tenofovir

2020
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-15, Volume: 71, Issue:12

    Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult

2020
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 92

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain

2020
Not all is perfect with Tenofovir alafenamide.
    HIV medicine, 2020, Volume: 21, Issue:6

    Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir

2020
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
    Annals of internal medicine, 2020, 02-18, Volume: 172, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome

2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Nucleotides; Platelet Count; Research Design; Risk; Tenofovir; Time Factors

2020
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
    Antiviral research, 2020, Volume: 179

    Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure

2020
An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Analytical biochemistry, 2020, 03-15, Volume: 593

    Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Formates; Humans; Prodrugs; Tandem Mass Spectrometry; Tenofovir

2020
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
    International journal of STD & AIDS, 2020, Volume: 31, Issue:4

    Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipid Metabolism; Risk Assessment; Tenofovir

2020
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?
    Annals of internal medicine, 2020, 05-05, Volume: 172, Issue:9

    Topics: Adenine; Alanine; Anti-HIV Agents; Cost-Benefit Analysis; Decision Making, Shared; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States

2020
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
    The Journal of infectious diseases, 2020, 07-23, Volume: 222, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Switzerland; Tenofovir

2020
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    AIDS (London, England), 2020, 05-01, Volume: 34, Issue:6

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain

2020
Hypophosphatemic Osteomalacia Due to Adefovir-Induced Fanconi Syndrome.
    The American journal of medicine, 2020, Volume: 133, Issue:12

    Topics: Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Female; Hepatitis C, Chronic; Humans; Hypophosphatemia; Organophosphonates; Osteomalacia; Tenofovir

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome

2020
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
    AIDS (London, England), 2020, 07-01, Volume: 34, Issue:8

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome

2020
Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
    International journal of pharmaceutics, 2020, May-30, Volume: 582

    Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Compounding; Female; Injections, Intravenous; Proof of Concept Study; Rats, Hairless; Tenofovir; Tissue Distribution; Transdermal Patch; Vagina

2020
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:5

    Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Tenofovir; Tissue Distribution; Treatment Outcome; Viral Load

2020
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
    Biomedica : revista del Instituto Nacional de Salud, 2020, 05-01, Volume: 40, Issue:Supl. 1

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Rilpivirine; Tenofovir

2020
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure

2020
Weighing considerations with newer antiretrovirals.
    The lancet. HIV, 2020, Volume: 7, Issue:6

    Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir

2020
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Antimicrobial agents and chemotherapy, 2020, 08-20, Volume: 64, Issue:9

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Fumarates; HIV Infections; Rabbits; Sheep; Tenofovir

2020
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
    Annals of internal medicine, 2020, 07-07, Volume: 173, Issue:1

    Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2020
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
    Annals of internal medicine, 2020, 07-07, Volume: 173, Issue:1

    Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2020
Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
    International journal of STD & AIDS, 2020, Volume: 31, Issue:10

    Topics: Acute Disease; Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lipase; Male; Pancreas; Pancreatitis; Piperazines; Pyridones; Tenofovir; Ultrasonography

2020
DISCOVER: much accomplished, but not yet for all.
    Lancet (London, England), 2020, 07-25, Volume: 396, Issue:10246

    Topics: Adenine; Alanine; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2020
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
    The Journal of antimicrobial chemotherapy, 2020, 10-01, Volume: 75, Issue:10

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir

2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
    The Journal of antimicrobial chemotherapy, 2020, 11-01, Volume: 75, Issue:11

    Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhibitors; Sofosbuvir; Tenofovir

2020
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:8

    Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load

2020
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:4

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir

2021
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    Journal of acquired immune deficiency syndromes (1999), 2020, 10-01, Volume: 85, Issue:2

    Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Interrupted Time Series Analysis; Kidney Diseases; Kidney Function Tests; Liver; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load

2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Annals of internal medicine, 2020, 09-15, Volume: 173, Issue:6

    Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Annals of internal medicine, 2020, 09-15, Volume: 173, Issue:6

    Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir

2020
Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 100

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rifabutin; Tenofovir; Viral Load

2020
Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
    Antiviral research, 2020, Volume: 183

    Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Cholesterol; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Membrane Potentials; Mitochondria; T-Lymphocytes; Tenofovir

2020
HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk.
    Circulation research, 2020, 11-06, Volume: 127, Issue:11

    Topics: 5'-Nucleotidase; Adenine; Alanine; Anti-HIV Agents; Apyrase; Blood Platelets; Cell Adhesion Molecules; Cell Communication; Cell-Derived Microparticles; Cells, Cultured; Dideoxynucleosides; Endothelial Cells; GPI-Linked Proteins; Human Umbilical Vein Endothelial Cells; Humans; Platelet Activation; Signal Transduction; Tenofovir; Thromboplastin

2020
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:10

    Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Nucleotides; Tenofovir

2020
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy.
    AIDS (London, England), 2020, 12-01, Volume: 34, Issue:15

    Topics: Adenine; Alanine; HIV Infections; Humans; Policy; Tenofovir

2020
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
    The Journal of antimicrobial chemotherapy, 2021, 02-11, Volume: 76, Issue:3

    Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir

2021
Editorial: tenofovir alafenamide fumarate-a new bullet to prevent mother-to-child transmission of hepatitis B virus. Authors' reply.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:11-12

    Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir

2020
Editorial: tenofovir alafenamide fumarate-a new silver bullet to prevent mother-to-child transmission of hepatitis B virus.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:11-12

    Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir

2020
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    AIDS and behavior, 2021, Volume: 25, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States

2021
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
    Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:3

    Topics: Adenine; Alanine; HIV Infections; Humans; Liver Transplantation; Retrospective Studies; Tenofovir

2021
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
    AIDS (London, England), 2021, 03-01, Volume: 35, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir

2021
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
    Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load

2020
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome; Viremia

2021
Assessment of the greenness of new stability indicating micellar UPLC and HPTLC methods for determination of tenofovir alafenamide in dosage forms.
    Journal of chromatographic science, 2021, Oct-29, Volume: 59, Issue:10

    Topics: Adenine; Alanine; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Micelles; Reproducibility of Results; Tablets; Tenofovir

2021
A rare case of acute tubular necrosis tenofovir alafenamide-related.
    Clinical nephrology, 2021, Volume: 95, Issue:6

    Topics: Adenine; Alanine; HIV Infections; Humans; Necrosis; Tenofovir

2021
Inhibition of Bitter Taste from Oral Tenofovir Alafenamide.
    Molecular pharmacology, 2021, Volume: 99, Issue:5

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Cell Line; Female; Flavones; Flavoring Agents; HEK293 Cells; Humans; Male; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Taste; Taste Buds; Tenofovir

2021
Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
    Journal of acquired immune deficiency syndromes (1999), 2021, 09-01, Volume: 88, Issue:1

    Topics: Adenine; Alanine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chromatography, Liquid; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Point-of-Care Systems; San Francisco; Tandem Mass Spectrometry; Tenofovir

2021
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome

2022
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
    The lancet. HIV, 2021, Volume: 8, Issue:6

    Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure

2021
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41 Suppl 1

    Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome

2021
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
    Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:3

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir

2022
A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
    Microbiology spectrum, 2021, 09-03, Volume: 9, Issue:1

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Edema; HIV Infections; HIV-1; Infusions, Subcutaneous; Male; Organophosphates; Pre-Exposure Prophylaxis; Rats; Tenofovir

2021
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    AIDS patient care and STDs, 2021, Volume: 35, Issue:8

    Topics: Adenine; Alanine; Anti-HIV Agents; Cohort Studies; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir

2021
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Journal of acquired immune deficiency syndromes (1999), 2021, 10-01, Volume: 88, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Tenofovir

2021
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
    Nature communications, 2021, 09-16, Volume: 12, Issue:1

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Drug Stability; Female; HIV Infections; HIV-1; Humans; Male; Nanoparticles; Organophosphates; Prodrugs; Rats, Sprague-Dawley; Tenofovir; Therapeutic Equivalency

2021
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:7

    Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir

2022
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
    Chinese medical journal, 2021, Oct-13, Volume: 134, Issue:23

    Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir

2021
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets.
    Journal of pharmaceutical and biomedical analysis, 2022, Jan-05, Volume: 207

    Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Fumarates; HIV Infections; Humans; Tablets; Tenofovir

2022
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
    International journal of STD & AIDS, 2022, Volume: 33, Issue:1

    Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome

2022
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Journal of the International AIDS Society, 2021, Volume: 24, Issue:11

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir

2021
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; Tenofovir

2022
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:2

    Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir

2022
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Journal of acquired immune deficiency syndromes (1999), 2022, 05-01, Volume: 90, Issue:1

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir

2022
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome

2021
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
    Hepatology international, 2022, Volume: 16, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome

2022
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:2

    Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir

2022
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
    The Journal of dermatology, 2022, Volume: 49, Issue:6

    Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepatitis B virus; Humans; Psoriasis; Tenofovir; Tumor Necrosis Factor Inhibitors

2022
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
    Journal of acquired immune deficiency syndromes (1999), 2022, 07-01, Volume: 90, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Protease Inhibitors; Tenofovir

2022
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:7

    Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir

2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
    AIDS (London, England), 2022, 09-01, Volume: 36, Issue:11

    Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir

2022
Tenofovir alafenamide fumarate.
    Antiviral therapy, 2022, Volume: 27, Issue:2

    Topics: Adenine; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Tenofovir

2022
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
    Scientific reports, 2022, 05-17, Volume: 12, Issue:1

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Mice; Tenofovir

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Milk, Human; Pregnancy; Tenofovir

2022
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35, Issue:4

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir

2022
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
    Obesity (Silver Spring, Md.), 2022, Volume: 30, Issue:6

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; Fumarates; HIV Infections; Humans; Retrospective Studies; Sustained Virologic Response; Tenofovir; Weight Gain

2022
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4

    Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome

2022
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4

    Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studies; Tenofovir

2022
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
    Medicine, 2022, Jun-24, Volume: 101, Issue:25

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome

2022
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    International journal of antimicrobial agents, 2022, Volume: 60, Issue:3

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia

2022
HBV in pregnancy: time to consider tenofovir alafenamide (TAF).
    Hepatology international, 2022, Volume: 16, Issue:4

    Topics: Adenine; Alanine; Female; Hepatitis B virus; HIV Infections; Humans; Pregnancy; Tenofovir

2022
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Journal of global antimicrobial resistance, 2022, Volume: 30

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir

2022
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
    Hepatology international, 2022, Volume: 16, Issue:4

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Tenofovir

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; Mothers; Tenofovir

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Human; Mothers; Tenofovir

2022
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
    BMC infectious diseases, 2022, Jul-14, Volume: 22, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir

2022
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
    AIDS (London, England), 2022, 11-15, Volume: 36, Issue:14

    Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA; Tenofovir

2022
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:5

    Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir

2022
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:5

    Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir

2022
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:11

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Maleates; Organophosphonates; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome

2022
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:6

    Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir

2022
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:6

    Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir

2022
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
    Biochemical pharmacology, 2022, Volume: 204

    Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Liquid; Ethanol; Fumarates; HIV; HIV Infections; Humans; Lipids; Organophosphates; Tandem Mass Spectrometry; Tenofovir

2022
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    Journal of acquired immune deficiency syndromes (1999), 2022, 10-01, Volume: 91, Issue:S1

    Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir

2022
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
    International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19

    Topics: Acute Kidney Injury; Adenine; Alanine; Antiviral Agents; Cisplatin; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney; Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome

2022
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 04-19, Volume: 80, Issue:9

    Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Kidney Failure, Chronic; Pyridones; Quality of Life; Renal Dialysis

2023
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
    International journal of STD & AIDS, 2023, Volume: 34, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Failure, Chronic; Peritoneal Dialysis

2023
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
    The Journal of antimicrobial chemotherapy, 2023, 03-02, Volume: 78, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Prospective Studies; Pyridones

2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
    HIV medicine, 2023, Volume: 24, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; Belgium; Cohort Studies; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Retrospective Studies; Treatment Outcome

2023
Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients.
    AIDS research and human retroviruses, 2023, Volume: 39, Issue:10

    Topics: Adenine; Anti-HIV Agents; Cholesterol; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Weight Gain

2023
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.
    HIV research & clinical practice, 2023, 07-20, Volume: 24, Issue:1

    Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome

2023